Vivos Therapeutics (VVOS) Assets Average (2021 - 2026)

Vivos Therapeutics (VVOS) has 6 years of Assets Average data on file, last reported at $25.1 million in Q1 2026.

• Assets Average for Q1 2026 came in at $25.1 million, up 88.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.1 million (up 88.94% YoY), and the FY2025 annual result was $20.2 million, up 55.44% from the prior year.
• Assets Average slipped to $25.1 million in Q1 2026 per VVOS's latest filing, from $25.4 million in the prior quarter.
• Over five years, Assets Average peaked at $31.6 million in Q1 2022 and troughed at $10.5 million in Q4 2023.
• A 5-year average of $18.5 million and a median of $15.6 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2026: Assets Average sank 57.01% in 2022, then jumped 88.94% in 2026.
• A 5-year view of Assets Average shows it stood at $16.1 million in 2022, then tumbled by 34.47% to $10.5 million in 2023, then soared by 45.54% to $15.3 million in 2024, then soared by 65.83% to $25.4 million in 2025, then dropped by 1.18% to $25.1 million in 2026.
• Business Quant data shows VVOS's Assets Average at $25.1 million in Q1 2026, $25.4 million in Q4 2025, and $25.8 million in Q3 2025.